Bladder and colorectal cancers are the fifth and ninth most common cancers in the world (2012). Their current standard of treatment is cold chemotherapy which, when coming into contact with cancer cells, have a low absorption rate. This ineffectiveness results in a high recurrence of the disease and an increasingly expensive cost of treatment.

Combat Medical’s proprietary technology (5 patents, 3 granted), which is CE marked and patent protected, uses heat to increase chemotherapy absorption rate by up to 10 times as well as stimulate the patient's natural immune response. This significantly reduces both recurrence rates and negative side effects of chemotherapy, whilst improving the chances of survival.

Since start of commercialisation in 2014, Combat Medical has sold over 200 devices and has completed over 20,000 treatments in over 35 countries. Having secured 28 distribution partners across the globe, the company is now planning to expand to the US and China. 

Lead by Edward Bruce-White, the company is now fundraising to capitalise on favourable market trends in the cancer treatment market and gain shares in international markets. 


Investment Highlights

  • Disruptive proprietary technology that can increase the absorption of chemotherapy by up 10X

  • Large addressable market estimated to be worth c. £6bn, targeting the third, fifth and ninth most common cancers

  • Impressive traction to date with over £1m 2017 revenue, having sold over 200 systems and delivered 20,000 treatments across 35 countries 

  • Favourable trends in the bladder cancer treatment market, with an opportunity to capitalise on the upcoming gap in supply 

  • Strong management team led by Edward Bruce White with over 15 years of experience in the medical device industry